中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 38 Issue 1
Jan.  2022
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(1): 35-41

Guidelines on the diagnosis and management of primary biliary cholangitis (2021)

DOI: 10.3760/cma.j.cn112138-20211112-00794
  • Received Date: 2021-12-25
  • Published Date: 2022-01-20
    Abstract
  • In 2015, the Chinese Society of Hepatology and Chinese Society of Gastroenterology issued the consensus on the diagnosis and management of primary biliary cholangitis (PBC). In the past years, more clinical studies have been reported in the field of PBC. To provide guidance to the clinical diagnosis and management of patients with PBC, the Chinese Society of Hepatology invited a panel of experts assessed the new clinical evidence and formulated the current guidelines which comprises 26 clinical recommendations.

     

    • FullText(HTML)
  • 志谢(以姓氏拼音排序):: 安纪红(内蒙古自治区人民医院感染科)、邓国宏(陆军军医大学第一附属医院传染科)、黄燕(中南大学湘雅医院传染科)、黄缘(北京清华长庚医院肝胆内科)、李荣宽(大连医科大学附属二院感染科)、李树臣(哈尔滨医科大学第二附属医院传染科)、陆海英(北京大学第一医院传染科)、石荔(西藏自治区人民医院感染科)、苏明华(广西医科大学第一附属医院感染科)、温志立(南昌大学第二附属医院消化内科)、吴彪(海南省人民医院感染科)、徐京杭(北京大学第一医院肝病科)、杨丽(四川大学华西医院消化内科)、杨积明(天津市第二人民医院感染科)、杨晋辉(昆明医科大学附属二院消化内科)、张缭云(山西医科大学第一医院传染科)、周璐(天津医科大学总医院消化内科)、周永健(广州市第一人民医院消化内科)、祖红梅(青海省第四人民医院传染科)参加本指南制定的讨论, 并提出了富有建设性的意见和建议。
    • References(113)
  • [1]
    LV T, CHEN S, LI M, et al. Regional variation and temporal trend of primary biliary cholangitis epidemiology: A systematic review and meta-analysis[J]. J Gastroenterol Hepatol, 2021, 36(6): 1423-1434. DOI: 10.1111/jgh.15329.
    [2]
    ZENG N, DUAN W, CHEN S, et al. Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region: A systematic review and meta-analysis[J]. Hepatol Int, 2019, 13(6): 788-799. DOI: 10.1007/s12072-019-09984-x.
    [3]
    MAYO MJ. Natural history of primary biliary cirrhosis[J]. Clin Liver Dis, 2008, 12(2): 277-288; viii. DOI: 10.1016/j.cld.2008.02.012.
    [4]
    PARÉS A, CABALLERÍA L, RODÉS J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid[J]. Gastroenterology, 2006, 130(3): 715-720. DOI: 10.1053/j.gastro.2005.12.029.
    [5]
    HARMS MH, van BUUREN HR, CORPECHOT C, et al. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis[J]. J Hepatol, 2019, 71(2): 357-365. DOI: 10.1016/j.jhep.2019.04.001.
    [6]
    GRANITO A, MURATORI P, QUARNETI C, et al. Antinuclear antibodies as ancillary markers in primary biliary cirrhosis[J]. Expert Rev Mol Diagn, 2012, 12(1): 65-74. DOI: 10.1586/erm.11.82.
    [7]
    LEUNG PS, ROSSARO L, DAVIS PA, et al. Antimitochondrial antibodies in acute liver failure: implications for primary biliary cirrhosis[J]. Hepatology, 2007, 46(5): 1436-1442. DOI: 10.1002/hep.21828.
    [8]
    ZHANG Q, LIU Z, WU S, et al. Meta-analysis of antinuclear antibodies in the diagnosis of antimitochondrial antibody-negative primary biliary cholangitis[J]. Gastroenterol Res Pract, 2019, 2019: 8959103. DOI: 10.1155/2019/8959103.
    [9]
    GRANITO A, MURATORI P, MURATORI L, et al. Antinuclear antibodies giving the 'multiple nuclear dots' or the 'rim-like/membranous' patterns: Diagnostic accuracy for primary biliary cirrhosis[J]. Aliment Pharmacol Ther, 2006, 24(11-12): 1575-1583. DOI: 10.1111/j.1365-2036.2006.03172.x.
    [10]
    CORPECHOT C, CARRAT F, POUJOL-ROBERT A, et al. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis[J]. Hepatology, 2012, 56(1): 198-208. DOI: 10.1002/hep.25599.
    [11]
    LUDWIG J, DICKSON ER, MCDONALD GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)[J]. Virchows Arch A Pathol Anat Histol, 1978, 379(2): 103-112. DOI: 10.1007/BF00432479.
    [12]
    GORDON SC, WU KH, LINDOR K, et al. Ursodeoxycholic acid treatmentpreferentially improves overall survival among African Americans with primary biliary cholangitis[J]. Am J Gastroenterol, 2020, 115(2): 262-270. DOI: 10.14309/ajg.0000000000000512.
    [13]
    ANGULO P, DICKSON ER, THERNEAU TM, et al. Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: A randomized trial[J]. J Hepatol, 1999, 30(5): 830-835. DOI: 10.1016/s0168-8278(99)80136-6.
    [14]
    ANGULO P, JORGENSEN RA, LINDOR KD. Incomplete response to ursodeoxycholic acid in primary biliary cirrhosis: Is a double dosage worthwhile?[J]. Am J Gastroenterol, 2001, 96(11): 3152-3157. DOI: 10.1111/j.1572-0241.2001.05270.x.
    [15]
    LINDOR KD, KOWDLEY KV, LUKETIC VA, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis[J]. Hepatology, 2009, 50(3): 808-814. DOI: 10.1002/hep.23082.
    [16]
    CHEN S, DUAN W, YOU H, et al. A brief review on prognostic models of primary biliary cholangitis[J]. Hepatol Int, 2017, 11(5): 412-418. DOI: 10.1007/s12072-017-9819-9.
    [17]
    CORPECHOT C, ABENAVOLI L, RABAHI N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis[J]. Hepatology, 2008, 48(3): 871-877. DOI: 10.1002/hep.22428.
    [18]
    CORPECHOT C, CHAZOUILLÈRES O, POUPON R. Early primary biliary cirrhosis: Biochemical response to treatment and prediction of long-term outcome[J]. J Hepatol, 2011, 55(6): 1361-1367. DOI: 10.1016/j.jhep.2011.02.031.
    [19]
    NEVENS F, ANDREONE P, MAZZELLA G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis[J]. N Engl J Med, 2016, 375(7): 631-643. DOI: 10.1056/NEJMoa1509840.
    [20]
    HIRSCHFIELD GM, BEUERS U, KUPCINSKAS L, et al. A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA[J]. J Hepatol, 2021, 74(2): 321-329. DOI: 10.1016/j.jhep.2020.09.011.
    [21]
    ZHANG LN, SHI TY, SHI XH, et al. Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis: Results of a 14-year cohort study[J]. Hepatology, 2013, 58(1): 264-272. DOI: 10.1002/hep.26322.
    [22]
    MANNE V, KOWDLEY KV. Obeticholic acid in primary biliary cholangitis: Where we stand[J]. Curr Opin Gastroenterol, 2019, 35(3): 191-196. DOI: 10.1097/MOG.0000000000000525.
    [23]
    TRAUNER M, NEVENS F, SHIFFMAN ML, et al. Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study[J]. Lancet Gastroenterol Hepatol, 2019, 4(6): 445-453. DOI: 10.1016/S2468-1253(19)30094-9.
    [24]
    PARÉS A, SHIFFMAN M, VARGAS V, et al. Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis[J]. Liver Int, 2020, 40(5): 1121-1129. DOI: 10.1111/liv.14429.
    [25]
    BOWLUS CL, POCKROS PJ, KREMER AE, et al. Long-term obeticholic acid therapy improves histological endpoints in patients with primary biliary cholangitis[J]. Clin Gastroenterol Hepatol, 2020, 18(5): 1170-1178. e6. DOI: 10.1016/j.cgh.2019.09.050.
    [26]
    KOWDLEY KV, LUKETIC V, CHAPMAN R, et al. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis[J]. Hepatology, 2018, 67(5): 1890-1902. DOI: 10.1002/hep.29569.
    [27]
    JOHN BV, SCHWARTZ K, LEVY C, et al. Impact of obeticholic acid exposure on decompensation and mortality in primary biliary cholangitis and cirrhosis[J]. Hepatol Commun, 2021, 5(8): 1426-1436. DOI: 10.1002/hep4.1720.
    [28]
    LINDOR KD, BOWLUS CL, BOYER J, et al. Primary biliary cholangitis: 2021 Practice Guidance Update from the American Association for the Study of Liver Diseases[J]. Hepatology, 2021. DOI: 10.1002/hep.32117.
    [29]
    ZHANG Y, LI S, HE L, et al. Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: A meta-analysis[J]. Drug Des Devel Ther, 2015, 9: 2757-2766. DOI: 10.2147/DDDT.S79837.
    [30]
    CORPECHOT C, CHAZOUILLÈRES O, ROUSSEAU A, et al. A placebo-controlled trial of bezafibrate in primary biliary cholangitis[J]. N Engl J Med, 2018, 378(23): 2171-2181. DOI: 10.1056/NEJMoa1714519.
    [31]
    de VRIES E, BOLIER R, GOET J, et al. Fibrates for Itch (FITCH) in fibrosing cholangiopathies: A double-blind, randomized, placebo-controlled trial[J]. Gastroenterology, 2021, 160(3): 734-743. e6. DOI: 10.1053/j.gastro.2020.10.001.
    [32]
    TANAKA A, HIROHARA J, NAKANO T, et al. Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis[J]. J Hepatol, 2021, 75(3): 565-571. DOI: 10.1016/j.jhep.2021.04.010.
    [33]
    CARRION AF, LINDOR KD, LEVY C. Safety of fibrates in cholestatic liver diseases[J]. Liver Int, 2021, 41(6): 1335-1343. DOI: 10.1111/liv.14871.
    [34]
    DOHMEN K, TANAKA H, HARUNO M. Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis[J]. Fukuoka Igaku Zasshi, 2013, 104(10): 350-361. http://catalog.lib.kyushu-u.ac.jp/handle/2324/1398604/p350.pdf
    [35]
    WANG L, SUN K, TIAN A, et al. Fenofibrate improves GLOBE and UK-PBC scores and histological features in primary biliary cholangitis[J]. Minerva Med, 2021. DOI: 10.23736/S0026-4806.21.07316-X.[Onlineaheadofprint]
    [36]
    RAUTIAINEN H, KÄRKKÄINEN P, KARVONEN AL, et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: A three-year randomized trial[J]. Hepatology, 2005, 41(4): 747-752. DOI: 10.1002/hep.20646.
    [37]
    LEUSCHNER M, MAIER KP, SCHLICHTING J, et al. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: Results of a prospective double-blind trial[J]. Gastroenterology, 1999, 117(4): 918-925. DOI: 10.1016/s0016-5085(99)70351-3.
    [38]
    HIRSCHFIELD GM, BEUERS U, KUPCINSKAS L, et al. A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA[J]. J Hepatol, 2021, 74(2): 321-329. DOI: 10.1016/j.jhep.2020.09.011.
    [39]
    HEMPFLING W, GRUNHAGE F, DILGER K, et al. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis[J]. Hepatology, 2003, 38(1): 196-202. DOI: 10.1053/jhep.2003.50266.
    [40]
    European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis[J]. J Hepatol, 2017, 67(1): 145-172. DOI: 10.1016/j.jhep.2017.03.022.
    [41]
    AGUILAR MT, CAREY EJ. Current status of liver transplantation for primary biliary cholangitis[J]. Clin Liver Dis, 2018, 22(3): 613-624. DOI: 10.1016/j.cld.2018.03.011.
    [42]
    MONTANO-LOZA AJ, HANSEN BE, CORPECHOT C, et al. Factors associated with recurrence of primary biliary cholangitis after liver transplantation and effects on graft and patient survival[J]. Gastroenterology, 2019, 156(1): 96-107. e1. DOI: 10.1053/j.gastro.2018.10.001.
    [43]
    SILVEIRA MG, TALWALKAR JA, LINDOR KD, et al. Recurrent primary biliary cirrhosis after liver transplantation[J]. Am J Transplant, 2010, 10(4): 720-726. DOI: 10.1111/j.1600-6143.2010.03038.x.
    [44]
    MONTANO-LOZA AJ, HANSEN BE, CORPECHOT C, et al. Factors associated with recurrence of primary biliary cholangitis after liver transplantation and effects on graft and patient survival[J]. Gastroenterology, 2019, 156(1): 96-107. e1. DOI: 10.1053/j.gastro.2018.10.001.
    [45]
    JACOB DA, NEUMANN UP, BAHRA M, et al. Liver transplantation for primary biliary cirrhosis: Influence of primary immunosuppression on survival[J]. Transplant Proc, 2005, 37(4): 1691-1692. DOI: 10.1016/j.transproceed.2005.03.130.
    [46]
    CORPECHOT C, CHAZOUILLÈRES O, BELNOU P, et al. Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis[J]. J Hepatol, 2020, 73(3): 559-565. DOI: 10.1016/j.jhep.2020.03.043.
    [47]
    CARBONE M, BUFTON S, MONACO A, et al. The effect of liver transplantation on fatigue in patients with primary biliary cirrhosis: A prospective study[J]. J Hepatol, 2013, 59(3): 490-494. DOI: 10.1016/j.jhep.2013.04.017.
    [48]
    SILVEIRA MG, GOSSARD AA, STAHLER AC, et al. A randomized, placebo-controlled clinical trial of efficacy and safety: Modafinil in the treatment of fatigue in patients with primary biliary cirrhosis[J]. Am J Ther, 2017, 24(2): e167-e176. DOI: 10.1097/MJT.0000000000000387.
    [49]
    SHAH RA, KOWDLEY KV. Mechanisms and treatments of pruritus in primary biliary cholangitis[J]. Semin Liver Dis, 2019, 39(2): 209-220. DOI: 10.1055/s-0039-1679918.
    [50]
    SCHAFFNER F, KLION FM, LATUFF AJ. The long term use of cholestyramine in the treatment of primary biliary cirrhosis[J]. Gastroenterology, 1965, 48: 293-298. http://europepmc.org/abstract/MED/14292140
    [51]
    TANDON P, ROWE BH, VANDERMEER B, et al. The efficacy and safety of bile acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus[J]. Am J Gastroenterol, 2007, 102(7): 1528-1536. DOI: 10.1111/j.1572-0241.2007.01200.x.
    [52]
    ATAEI S, KORD L, LARKI A, et al. Comparison of sertraline with rifampin in the treatment of cholestatic pruritus: A randomized clinical trial[J]. Rev Recent Clin Trials, 2019, 14(3): 217-223. DOI: 10.2174/1574887114666190328130720.
    [53]
    JONES DE, NEWTON JL. An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis[J]. Aliment Pharmacol Ther, 2007, 25(4): 471-476. DOI: 10.1111/j.1365-2036.2006.03223.x.
    [54]
    HEGADE VS, PECHLIVANIS A, MCDONALD J, et al. Autotaxin, bile acid profile and effect of ileal bile acid transporter inhibition in primary biliary cholangitis patients with pruritus[J]. Liver Int, 2019, 39(5): 967-975. DOI: 10.1111/liv.14069.
    [55]
    AL-DURY S, WAHLSTRÖM A, WAHLIN S, et al. Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis[J]. Sci Rep, 2018, 8(1): 6658. DOI: 10.1038/s41598-018-25214-0.
    [56]
    TATLIPINAR S, AKPEK EK. Topical ciclosporin in the treatment of ocular surface disorders[J]. Br J Ophthalmol, 2005, 89(10): 1363-1367. DOI: 10.1136/bjo.2005.070888.
    [57]
    VITALI C, MINNITI A, PIGNATARO F, et al. Management of Sjögren's Syndrome: Present issues and future perspectives[J]. Front Med (Lausanne), 2021, 8: 676885. DOI: 10.3389/fmed.2021.676885.
    [58]
    SEKI A, IKEDA F, MIYATAKE H, et al. Risk of secondary osteoporosis due to lobular cholestasis in non-cirrhotic primary biliary cholangitis[J]. J Gastroenterol Hepatol, 2017, 32(9): 1611-1616. DOI: 10.1111/jgh.13746.
    [59]
    TRIVEDI HD, DANFORD CJ, GOYES D, et al. Osteoporosis in primary biliary cholangitis: Prevalence, impact and management challenges[J]. Clin Exp Gastroenterol, 2020, 13: 17-24. DOI: 10.2147/CEG.S204638.
    [60]
    RUDIC JS, GILJACA V, KRSTIC MN, et al. Bisphosphonates for osteoporosis in primary biliary cirrhosis[J]. Cochrane Database Syst Rev, 2011, (12): CD009144. DOI: 10.1002/14651858.CD009144.pub2.
    [61]
    DANFORD CJ, EZAZ G, TRIVEDI HD, et al. The pharmacologic management of osteoporosis in primary biliary cholangitis: A systematic review and meta-analysis[J]. J Clin Densitom, 2020, 23(2): 223-236. DOI: 10.1016/j.jocd.2019.05.003.
    [62]
    GUAÑABENS N, MONEGAL A, CERDÁ D, et al. Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis[J]. Hepatology, 2013, 58(6): 2070-2078. DOI: 10.1002/hep.26466.
    [63]
    WANG Z, PENG C, WANG P, et al. Serum vitamin D level is related to disease progression in primary biliary cholangitis[J]. Scand J Gastroenterol, 2020, 55(11): 1333-1340. DOI: 10.1080/00365521.2020.1829030.
    [64]
    European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease[J]. J Hepatol, 2019, 70(1): 172-193. DOI: 10.1016/j.jhep.2018.06.024.
    [65]
    LINDOR KD, BOWLUS CL, BOYER J, et al. Primary biliary cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases[J]. Hepatology, 2019, 69(1): 394-419. DOI: 10.1002/hep.30145.
    [66]
    KANIS JA, COOPER C, RIZZOLI R, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women[J]. Osteoporos Int, 2019, 30(1): 3-44. DOI: 10.1007/s00198-018-4704-5.
    [67]
    FLOREANI A, ZAPPALA F, FRIES W, et al. A 3-year pilot study with 1, 25-dihydroxyvitamin D, calcium, and calcitonin for severe osteodystrophy in primary biliary cirrhosis[J]. J Clin Gastroenterol, 1997, 24(4): 239-244. DOI: 10.1097/00004836-199706000-00012.
    [68]
    GATSELIS NK, DALEKOS GN. Molecular diagnostic testing for primary biliary cholangitis[J]. Expert Rev Mol Diagn, 2016, 16(9): 1001-1010. DOI: 10.1080/14737159.2016.1217159.
    [69]
    CHEN S, DUAN W, LI M, et al. Prognosis of 732 ursodeoxycholic acid-treated patients with primary biliary cholangitis: A single center follow-up study from China[J]. J Gastroenterol Hepatol, 2019, 34(7): 1236-1241. DOI: 10.1111/jgh.14521.
    [70]
    INVERNIZZI P, CROSIGNANI A, BATTEZZATI PM, et al. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis[J]. Hepatology, 1997, 25(5): 1090-1095. DOI: 10.1002/hep.510250507.
    [71]
    JULIUSSON G, IMAM M, BJÖRNSSON ES, et al. Long-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis[J]. Scand J Gastroenterol, 2016, 51(6): 745-752. DOI: 10.3109/00365521.2015.1132337.
    [72]
    SAKAUCHI F, MORI M, ZENIYA M, et al. Antimitochondrial antibody negative primary biliary cirrhosis in Japan: Utilization of clinical data when patients applied to receive public financial aid[J]. J Epidemiol, 2006, 16(1): 30-34. DOI: 10.2188/jea.16.30.
    [73]
    HIRSCHFIELD GM, HEATHCOTE EJ. Antimitochondrial antibody-negative primary biliary cirrhosis[J]. Clin Liver Dis, 2008, 12(2): 323-331; viii-ix. DOI: 10.1016/j.cld.2008.02.003.
    [74]
    JIN Q, MORITOKI Y, LLEO A, et al. Comparative analysis of portal cell infiltrates in antimitochondrial autoantibody-positive versus antimitochondrial autoantibody- negative primary biliary cirrhosis[J]. Hepatology, 2012, 55(5): 1495-1506. DOI: 10.1002/hep.25511.
    [75]
    DAHLQVIST G, GAOUAR F, CARRAT F, et al. Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis[J]. Hepatology, 2017, 65(1): 152-163. DOI: 10.1002/hep.28859.
    [76]
    ZANDANELL S, STRASSER M, FELDMAN A, et al. Low rate of new-onset primary biliary cholangitis in a cohort of anti-mitochondrial antibody-positive subjects over six years of follow-up[J]. J Intern Med, 2020, 287(4): 395-404. DOI: 10.1111/joim.13005.
    [77]
    GULAMHUSEIN AF, JURAN BD, ATKINSON EJ, et al. Low incidence of primary biliary cirrhosis (PBC) in the first-degree relatives of PBC probands after 8 years of follow-up[J]. Liver Int, 2016, 36(9): 1378-1382. DOI: 10.1111/Liv.13143.
    [78]
    SUN C, XIAO X, YAN L, et al. Histologically proven AMA positive primary biliary cholangitis but normal serum alkaline phosphatase: Is alkaline phosphatase truly a surrogate marker?[J]. J Autoimmun, 2019, 99: 33-38. DOI: 10.1016/j.jaut.2019.01.005.
    [79]
    TERZIROLI BERETTA-PICCOLI B, STIRNIMANN G, MERTENS J, et al. Primary biliary cholangitis with normal alkaline phosphatase: A neglected clinical entity challenging current guidelines[J]. J Autoimmun, 2021, 116: 102578. DOI: 10.1016/j.jaut.2020.102578.
    [80]
    LOHSE AW, ZUM BVSCHENFELDE KH, FRANZ B, et al. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: Evidence for it being a hepatitic form of PBC in genetically susceptible individuals[J]. Hepatology, 1999, 29(4): 1078-1084. DOI: 10.1002/hep.510290409.
    [81]
    LEE BT, WANG Y, YANG A, et al. IgG: IgM ratios of liver plasma cells reveal similar phenotypes of primary biliary cholangitis with and without features of autoimmune hepatitis[J]. Clin Gastroenterol Hepatol, 2021, 19(2): 397-399. DOI: 10.1016/j.cgh.2019.11.024.
    [82]
    CHAZOUILLÈRES O, WENDUM D, SERFATY L, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: Clinical features and response to therapy[J]. Hepatology, 1998, 28(2): 296-301. DOI: 10.1002/hep.510280203.
    [83]
    YANG F, WANG Q, BIAN Z, et al. Autoimmune hepatitis: East meets west[J]. J Gastroenterol Hepatol, 2015, 30(8): 1230-1236. DOI: 10.1111/jgh.12952.
    [84]
    WANG Q, SELMI C, ZHOU X, et al. Epigenetic considerations and the clinical reevaluation of the overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis[J]. J Autoimmun, 2013, 41: 140-145. DOI: 10.1016/j.jaut.2012.10.004.
    [85]
    MURATORI P, GRANITO A, PAPPAS G, et al. The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome[J]. Am J Gastroenterol, 2009, 104(6): 1420-1425. DOI: 10.1038/ajg.2009.126.
    [86]
    EFE C, PURNAK T, OZASLAN E, et al. The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome[J]. Am J Gastroenterol, 2010, 105(1): 226; author reply 226-227. DOI: 10.1038/ajg.2009.602.
    [87]
    BOBERG KM, CHAPMAN RW, HIRSCHFIELD GM, et al. Overlap syndromes: The International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue[J]. J Hepatol, 2011, 54(2): 374-385. DOI: 10.1016/j.jhep.2010.09.002.
    [88]
    KUIPER EM, ZONDERVAN PE, VAN BUUREN HR. Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome[J]. Clin Gastroenterol Hepatol, 2010, 8(6): 530-534. DOI: 10.1016/j.cgh.2010.03.004.
    [89]
    YANG F, WANG Q, WANG Z, et al. The natural history and prognosis of primary biliary cirrhosis with clinical features of autoimmune hepatitis[J]. Clin Rev Allergy Immunol, 2016, 50(1): 114-123. DOI: 10.1007/s12016-015-8516-5.
    [90]
    FREEDMAN BL, DANFORD CJ, PATWARDHAN V, et al. Treatment of overlap syndromes in autoimmune liver disease: A systematic review and meta-analysis[J]. J Clin Med, 2020, 9(5). DOI: 10.3390/jcm9051449.
    [91]
    ZHANG H, LI S, YANG J, et al. A meta-analysis of ursodeoxycholic acid therapy versus combination therapy with corticosteroids for PBC-AIH-overlap syndrome: Evidence from 97 monotherapy and 117 combinations[J]. Prz Gastroenterol, 2015, 10(3): 148-155. DOI: 10.5114/pg.2015.51187.
    [92]
    OZASLAN E, EFE C, HEURGUÉ-BERLOT A, et al. Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis[J]. Clin Gastroenterol Hepatol, 2014, 12(5): 863-869. DOI: 10.1016/j.cgh.2013.09.021.
    [93]
    MAGO S, WU GY. Primary sclerosing cholangitis and primary biliary cirrhosis overlap syndrome: A review[J]. J Clin Transl Hepatol, 2020, 8(3): 336-346. DOI: 10.14218/JCTH.2020.00036.
    [94]
    FLOREANI A, INFANTOLINO C, FRANCESCHET I, et al. Pregnancy and primary biliary cirrhosis: A case-control study[J]. Clin Rev Allergy Immunol, 2015, 48(2-3): 236-242. DOI: 10.1007/s12016-014-8433-z.
    [95]
    TRIVEDI PJ, KUMAGI T, AL-HARTHY N, et al. Good maternal and fetal outcomes for pregnant women with primary biliary cirrhosis[J]. Clin Gastroenterol Hepatol, 2014, 12(7): 1179-1185. e1. DOI: 10.1016/j.cgh.2013.11.030.
    [96]
    CAULDWELL M, MACKIE FL, STEER PJ, et al. Pregnancy outcomes in women with primary biliary cholangitis and primary sclerosing cholangitis: A retrospective cohort study[J]. BJOG, 2020, 127(7): 876-884. DOI: 10.1111/1471-0528.16119.
    [97]
    EFE C, KAHRAMANO G Ǧ LU-AKSOY E, YILMAZ B, et al. Pregnancy in women with primary biliary cirrhosis[J]. Autoimmun Rev, 2014, 13(9): 931-935. DOI: 10.1016/j.autrev.2014.05.008.
    [98]
    HEMPFLING W, DILGER K, BEUERS U. Systematic review: Ursodeoxycholic acid-adverse effects and drug interactions[J]. Aliment Pharmacol Ther, 2003, 18(10): 963-972. DOI: 10.1046/j.1365-2036.2003.01792.x.
    [99]
    OVADIA C, SAJOUS J, SEED PT, et al. Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: A systematic review and individual participant data meta-analysis[J]. Lancet Gastroenterol Hepatol, 2021, 6(7): 547-558. DOI: 10.1016/S2468-1253(21)00074-1.
    [100]
    RUDI J, SCHÖNIG T, STREMMEL W. Therapy with ursodeoxycholic acid in primary biliary cirrhosis in pregnancy[J]. Z Gastroenterol, 1996, 34(3): 188-191.
    [101]
    VÍTEK L, ZELENKOVÁ M, BRǓHA R. Safe use of ursodeoxycholic acid in a breast-feeding patient with primary biliary cirrhosis[J]. Dig Liver Dis, 2010, 42(12): 911-912. DOI: 10.1016/j.dld.2010.06.002.
    [102]
    BRITES D, RODRIGUES CM. Elevated levels of bile acids in colostrum of patients with cholestasis of pregnancy are decreased following ursodeoxycholic acid therapy[J]. J Hepatol, 1998, 29(5): 743-751. DOI: 10.1016/s0168-8278(98)80255-9.
    [103]
    FAN X, WANG T, SHEN Y, et al. Underestimated male prevalence of primary biliary cholangitis in China: Results of a 16-yr cohort study involving 769 patients[J]. Sci Rep, 2017, 7(1): 6560. DOI: 10.1038/s41598-017-06807-7.
    [104]
    NATARAJAN Y, TANSEL A, PATEL P, et al. Incidence of hepatocellular carcinoma in primary biliary cholangitis: A systematic review and meta-analysis[J]. Dig Dis Sci, 2021, 66(7): 2439-2451. DOI: 10.1007/s10620-020-06498-7.
    [105]
    NAKAMURA M, KONDO H, TANAKA A, et al. Autoantibody status and histological variables influence biochemical response to treatment and long-term outcomes in Japanese patients with primary biliary cirrhosis[J]. Hepatol Res, 2015, 45(8): 846-855. DOI: 10.1111/hepr.12423.
    [106]
    POUPON R, CHAZOUILLÉRES O, BALKAU B, et al. Clinical and biochemical expression of the histopathological lesions of primary biliary cirrhosis. UDCA-PBC Group[J]. J Hepatol, 1999, 30(3): 408-412. DOI: 10.1016/s0168-8278(99)80098-1.
    [107]
    NAKANUMA Y, HOSO M, MIZUNO Y, et al. Pathologic study of primary biliary cirrhosis of early histologic stages presenting cholestatic jaundice[J]. Liver, 1988, 8(6): 319-324. DOI: 10.1111/j.1600-0676.1988.tb01010.x.
    [108]
    HARADA K, HSU M, IKEDA H, et al. Application and validation of a new histologic staging and grading system for primary biliary cirrhosis[J]. J Clin Gastroenterol, 2013, 47(2): 174-181. DOI: 10.1097/MCG.0b013e31827234e4.
    [109]
    LAMMERS WJ, HIRSCHFIELD GM, CORPECHOT C, et al. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy[J]. Gastroenterology, 2015, 149(7): 1804-1812. e4. DOI: 10.1053/j.gastro.2015.07.061.
    [110]
    CARBONE M, SHARP SJ, FLACK S, et al. The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis[J]. Hepatology, 2016, 63(3): 930-950. DOI: 10.1002/hep.28017.
    [111]
    YANG F, YANG Y, WANG Q, et al. The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: The additional effect of anti-gp210[J]. Aliment Pharmacol Ther, 2017, 45(5): 733-743. DOI: 10.1111/apt.13927.
    [112]
    EFE C, TAȘÇILAR K, HENRIKSSON I, et al. Validation of risk scoring systems in ursodeoxycholic acid-treated patients with primary biliary cholangitis[J]. Am J Gastroenterol, 2019, 114(7): 1101-1108. DOI: 10.14309/ajg.0000000000000290.
    [113]
    LAZARIDIS KN, JURAN BD, BOE GM, et al. Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis[J]. Hepatology, 2007, 46(3): 785-792. DOI: 10.1002/hep.21749.
    • Relative Articles

  • Relative Articles

    [1]Qiupeng WANG, Meifu GAN. Pathological diagnosis of primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2024, 40(6): 1088-1092. doi: 10.12449/JCH240604
    [2]Haifeng LIU, Simin ZHOU, Jiwen LI, Jiangpeng LIU, Bangmao WANG, Lu ZHOU. Effect of depression on response to ursodeoxycholic acid and the occurrence of liver cirrhosis in patients with primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2023, 39(12): 2817-2823. doi: 10.3969/j.issn.1001-5256.2023.12.011
    [3]Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the diagnosis and management of primary sclerosing cholangitis (2021)[J]. Journal of Clinical Hepatology, 2022, 38(1): 50-61. doi: 10.3760/cma.j.cn112138-20211109-00786
    [4]Xing LYU, Ting LI, Xiaodong SUN, Jianpeng ZHOU, Dongxia WANG, Guoyue LYU. Research advances in the treatment of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2022, 38(9): 2130-2135. doi: 10.3969/j.issn.1001-5256.2022.09.035
    [5]Fang QIU, Chan WANG, Mingming ZHANG, Xingjuan SHI, Xiangdong LIU. Genetic studies of primary biliary cholangitis in the post-GWAS era[J]. Journal of Clinical Hepatology, 2022, 38(4): 759-761. doi: 10.3969/j.issn.1001-5256.2022.04.005
    [6]Lin HAN, Qingsheng LIANG, Huan XIE, Ying CHEN, Jun ZHAO, Mingyue ZHANG, Baosen LI, Yanli DONG, Ying SUN. Value of baseline IgM level in predicting the treatment response of primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2022, 38(4): 815-820. doi: 10.3969/j.issn.1001-5256.2022.04.015
    [7]Jing ZHU, Yanhang GAO. Recommendations for APASL clinical practice guidance: The diagnosis and management of patients with primary biliary cholangitis (2022)[J]. Journal of Clinical Hepatology, 2022, 38(2): 318-319. doi: 10.3969/j.issn.1001-5256.2022.02.012
    [8]Mei CHEN, Ning MA, Jingbo JIN, Yu PENG, Sitong FAN, Fang WANG. A case of primary biliary cholangitis with megaloblastic anemia[J]. Journal of Clinical Hepatology, 2022, 38(5): 1114-1115. doi: 10.3969/j.issn.1001-5256.2022.05.026
    [9]Haitao MA, Yingmei TANG. Research advances in exosomes in primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2022, 38(8): 1896-1900. doi: 10.3969/j.issn.1001-5256.2022.08.035
    [10]Wang XiaoJing, Liu Yao, Wang XianBo. Biochemical response and integrated traditional Chinese and Western medicine therapy for primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2020, 36(1): 26-30. doi: 10.3969/j.issn.1001-5256.2020.01.004
    [11]Qin TingTing, Zhang Yu, Shao YueMing, Yin Xin, Wen XiaoYu. Primary biliary cholangitis with acute myeloid leukemia: A case report[J]. Journal of Clinical Hepatology, 2020, 36(8): 1827-1828. doi: 10.3969/j.issn.1001-5256.2020.08.031
    [12]Wei Jing, Wu XiRun. Current status of research on fibrates in treatment of primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2020, 36(2): 442-445. doi: 10.3969/j.issn.1001-5256.2020.02.046
    [13]Yang Ning, Liu YanSheng, Han Ying. Diagnosis and treatment of primary biliary cholangitis-autoimmune hepatitis overlap syndrome[J]. Journal of Clinical Hepatology, 2020, 36(3): 697-700. doi: 10.3969/j.issn.1001-5256.2020.03.051
    [14]Wang Jing, Zhao LiLi, Shi RuiFang, Liu YongGang, Li Jia. Early treatment of PBC-AIH overlap syndrome with histological remission: A case report[J]. Journal of Clinical Hepatology, 2019, 35(9): 2059-2061. doi: 10.3969/j.issn.1001-5256.2019.09.037
    [15]Yang QianQian, Ren TianQi, Xue ShuWen, Chen QingLing, Feng LiNa, Zhang XiaoXue, Wen XiaoYu, Jin QingLong. Primary biliary cholangitis with myelofibrosis: A case report[J]. Journal of Clinical Hepatology, 2019, 35(9): 2057-2058. doi: 10.3969/j.issn.1001-5256.2019.09.036
    [16]Wang Jing, Zhang BiQing, Pan YunZhi, Zhu ChuanWu. Role of microRNA in the pathogenesis, diagnosis, and outcome evaluation of primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2019, 35(7): 1636-1639. doi: 10.3969/j.issn.1001-5256.2019.07.047
    [17]Wang Lu, Han Ying. An excerpt of primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases[J]. Journal of Clinical Hepatology, 2018, 34(11): 2300-2304. doi: 10.3969/j.issn.1001-5256.2018.11.007
    [18]Gao Feng, Zhang FuKui, Jia JiDong. Liver function changes of ursodeoxycholic acid made in china for patients with primary biliary cirrhosis.[J]. Journal of Clinical Hepatology, 2008, 24(4): 278-280.
    [19]Tang ShuZhen, Liu XiaoMing, You Hong, Zhang FuKui, Wang BaoEn, Jia JiDong. Autoimmune related clinical tests in diagnosis of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2006, 22(3): 191-192.
    [20]He WenTao, Shi JianShi. Clinical analysis of primary bilary cirrhosis.[J]. Journal of Clinical Hepatology, 2001, 17(3): 180-181.
    • Supplements(0)
    • Cited By

  • Cited by

    Periodical cited type(64)

    1. 严丽英，过建春. 过建春教授论治原发性胆汁性胆管炎经验. 中西医结合肝病杂志. 2025(01): 90-92 .
    2. 赵应灿，申东方，范才. 腹腔镜联合胆道镜切开取石术治疗结石性梗阻性胆管炎的效果观察. 黑龙江医学. 2025(02): 166-168 .
    3. 张新驰，熊雨凡，顾静，李莹莹，魏虹合，李欣忆，李娇娇，甘建和，孙蔚，陈丽. 熊去氧胆酸治疗原发性胆汁性胆管炎患者疗效及其对血脂水平的影响. 胃肠病学和肝病学杂志. 2025(02): 254-257 .
    4. 李诗国，潘铨，江丽平，陈文晓，金佩伦. 畲药地稔滋肾方联合针刺辅助治疗原发性胆汁性胆管炎肝肾阴虚证32例临床观察. 中医杂志. 2024(02): 198-204 .
    5. 高司成，柴海生，杨海琳，王一凤，喻晓，祝峻峰. 中药联合熊脱氧胆酸治疗老年女性原发性胆汁性肝硬化失代偿期的临床疗效. 上海中医药杂志. 2024(02): 79-83 .
    6. 张贺媛，王芳，吴璇，刘雪姣，黄春洋，王璇. 水飞蓟宾联合熊去氧胆酸对原发性胆汁性肝硬化患者临床疗效及肝功能的影响. 中国药业. 2024(05): 105-108 .
    7. 马丹彤，李洪杰，段雪飞. ABCB11基因突变致良性复发性肝内胆汁淤积症2型1例. 肝脏. 2024(02): 251-253 .
    8. 李秉翰，薛淋淋，刘立. 原发性胆汁性胆管炎患者发生呼吸系统细菌感染的列线图预测模型构建及评价. 内蒙古医学杂志. 2024(02): 139-146 .
    9. 马丽玲，朱启泰，徐俊驰，胥萍，吴敏娟. 肝功能指标与自身抗体指标对自身免疫性肝病鉴别诊断的价值. 抗感染药学. 2024(01): 64-69 .
    10. 杨子轩，卢秉久. 中西医治疗原发性胆汁性胆管炎研究进展. 实用中医内科杂志. 2024(05): 78-81 .
    11. 王秋鹏，甘梅富. 原发性胆汁性胆管炎的病理学诊断. 临床肝胆病杂志. 2024(06): 1088-1092 . 本站查看
    12. 田思佳，李江燕，魏婷婷，张婷，梁艳. 原发性胆汁性胆管炎伴多发性骨髓瘤1例报告. 海军军医大学学报. 2024(06): 781-783 .
    13. 刘尧，高方媛，陈佳良，毕于斐，王晓静，周桂琴，冯颖，王宪波. 疏肝利胆健脾方对原发性胆汁性胆管炎生化应答不佳高风险患者的疗效观察. 北京中医药. 2024(06): 586-589 .
    14. 李梦羽，叶思雯，王妍，许笑宇，张玮. 原发性胆汁性胆管炎认知障碍与中医体质的关系研究. 北京中医药. 2024(06): 594-599 .
    15. 王宪波，毕于斐，时克，冯颖. 复方中药联合熊去氧胆酸治疗原发性胆汁性胆管炎临床疗效与作用机制. 北京中医药. 2024(06): 582-585 .
    16. 赵进玉，林延延，岳平，姚佳，米宁宁，李麻图，付文康，高龙，Suzuki Azumi，Wong Peng F，Tanaka Kiyohito，Rerknimitr Rungsun，Junger Henrik H，Cheung Tan T，Melloul Emmanuel，Demartines Nicolas，Leung Joseph W，袁金秋，Schlitt Hans J，孟文勃. 胆道纤维化的发生发展与治疗. 中华消化外科杂志. 2024(07): 989-1000 .
    17. 袁琳娜，陈一晖，那恒彬，鲁杰，刘叶，李武. 原发性胆汁性胆管炎合并代谢相关脂肪性肝病的临床特征及危险因素分析. 临床肝胆病杂志. 2024(08): 1598-1604 . 本站查看
    18. 张明明，刘寰，张冬梅，吴东波，唐红. 原发性胆汁性胆管炎-自身免疫性肝炎重叠综合征合并肺隐球菌病1例报告. 临床肝胆病杂志. 2024(08): 1666-1669 . 本站查看
    19. 冯月香，郝长河，逄金霞，苏超，焦克德. 耳尖放血对肝硬化黄疸致皮肤瘙痒患者治疗效果及生活质量的影响. 名医. 2024(07): 12-14 .
    20. 陈沁磊，陆玮婷，乔飞，史会连，张帆，徐祥涛. 原发性胆汁性胆管炎不同证型与肝组织病理相关性研究. 河北中医. 2024(09): 1488-1492 .
    21. 张梓珊，张耀武，李梦桃. 治疗原发性胆汁性胆管炎的新型药物综述. 中西医结合肝病杂志. 2024(08): 749-754 .
    22. 张帆，乔飞，郭海燕，陆玮婷，徐祥涛，袁征，史会连. PBC患者中医证型、EB病毒壳抗原IgA抗体表达情况与临床特征及病理分期的研究. 中西医结合肝病杂志. 2024(08): 687-690+699 .
    23. 任艳，孔明，徐曼曼，白丽，陈煜. 瞬时弹性成像技术和无创诊断模型诊断原发性胆汁性胆管炎患者肝纤维化效能研究. 实用肝脏病杂志. 2024(05): 725-728 .
    24. 高怡，沈小雪，夏素芹，张洁，朱先兰. 自身免疫性肝炎和原发性胆汁性胆管炎患者血清胆汁酸成分变化及其对治疗应答的影响. 实用肝脏病杂志. 2024(05): 709-712 .
    25. 王燕燕，周桐桐，卞兆连. 原发性胆汁性胆管炎和原发性胆汁性胆管炎-自身免疫性肝炎重叠综合征患者临床与肝组织病理学特点分析. 实用肝脏病杂志. 2024(05): 721-724 .
    26. 王雪梅，张瑶，王米雪，王跃龙，王玥. 多模态超声及生化指标对原发性胆汁性胆管炎患者病理学分期的预测价值. 中国超声医学杂志. 2024(08): 902-904 .
    27. 张梓珊，张耀武，董晓明，高雪. 阿法骨化醇联合熊去氧胆酸对原发性胆汁性胆管炎的疗效研究. 中国临床药理学与治疗学. 2024(10): 1161-1167 .
    28. 王宪波. 原发性胆汁性胆管炎中西医结合诊疗专家共识. 临床肝胆病杂志. 2024(09): 1757-1766 . 本站查看
    29. 李娟，哈小琴，卢利霞. 自身免疫性肝病发病机制的研究进展. 实用临床医药杂志. 2024(17): 137-142 .
    30. 王杰，周涛，喻凯凯，程良斌，蔡岳. 程良斌治疗胆汁淤积性肝病相关瘙痒症的临床经验. 中国医药导报. 2024(24): 155-158 .
    31. 周丽君，郭玉婷. 原发性硬化性胆管炎合并重度溃疡性结肠炎1例. 光明中医. 2024(19): 3977-3980 .
    32. 李茂，刘敏，张亚琳，罗惠心，宋黎，彭科，陆茂. 系统性硬化症合并原发性胆汁性胆管炎重叠综合征1例. 中国皮肤性病学杂志. 2024(11): 1265-1269 .
    33. 李瑶，刘昱旸，钱俊，马雄，王绮夏. 原发性胆汁性胆管炎患者临床显著性门静脉高压的危险因素分析和预测模型建立. 胃肠病学. 2024(03): 129-134 .
    34. 马铭涵，刘彦琦. 以肠道菌群为靶点治疗原发性胆汁性胆管炎的临床应用. 临床肝胆病杂志. 2023(01): 188-192 . 本站查看
    35. 于盈盈，吕文良. 吕文良教授从肝脾论治原发性胆汁性胆管炎的经验. 中国医药导报. 2023(05): 133-136+141 .
    36. 童雅茹，尹晓春，张玮，孙畅，张明，诸葛宇征. 经颈静脉肝内门体分流术治疗原发性胆汁性胆管炎伴门静脉高压的效果评估. 临床肝胆病杂志. 2023(02): 333-338 . 本站查看
    37. 张丽丽，张纯，王一同，勾春燕，胡建华，吕文良. 系统性硬化病合并原发性胆汁性胆管炎并发门静脉高压症12例临床特点分析. 实用肝脏病杂志. 2023(02): 230-233 .
    38. 刘红丽，杨永峰. 原发性胆汁性胆管炎诊治——病理是否必需?. 临床肝胆病杂志. 2023(03): 511-516 . 本站查看
    39. 许永伟，谢旭华，毛重山. 熊去氧胆酸联合五酯胶囊、醋酸泼尼松治疗对代偿期原发性胆汁性肝硬化患者肝功能、肝纤维化与免疫功能的影响. 内科. 2023(01): 82-85+94 .
    40. 肖倩，谭善忠，蒋淑莲，梁重峰，陈小妹. 自身免疫性肝炎-原发性胆汁性胆管炎重叠综合征湿热瘀阻证与湿热中阻证的临床病理特征分析. 中医药导报. 2023(04): 88-91+97 .
    41. 薛淋淋，李秉翰，刘春云，李卫昆，常丽仙，刘立. 肝硬化合并脓毒症患者短期住院死亡的Cox比例风险预测模型建立及评价. 临床肝胆病杂志. 2023(05): 1089-1097 . 本站查看
    42. 李力晨，汤绍辉. 自身免疫性肝炎-原发性胆汁性胆管炎重叠综合征合并胃腺癌1例报告. 临床肝胆病杂志. 2023(05): 1150-1153 . 本站查看
    43. 刘亚兴，刘尧，周桂琴，蔡静，冯颖，王晓静，陈佳良，王宪波. 原发性胆汁性胆管炎发生肝硬化失代偿危险因素评估病例对照研究. 中西医结合肝病杂志. 2023(05): 402-406 .
    44. 姚子昂，赵鑫，吕文良，张丽丽，强睿. 基于数据挖掘探讨吕文良教授治疗自身免疫性肝病的用药规律. 中国医药导报. 2023(15): 4-11 .
    45. 刘庆夏，张成港，唐浩淋，渠文静，季慧范，郭晓林. 原发性胆汁性胆管炎合并结缔组织病及免疫性血小板减少症1例报告. 临床肝胆病杂志. 2023(06): 1404-1407 . 本站查看
    46. 杨航，赵黎莉，韩萍，陈庆灵，文君，刘洁，程晓静，李嘉. 血清壳多糖酶3样蛋白1(CHI3L1)对肝硬化患者发生失代偿事件风险的预测价值. 临床肝胆病杂志. 2023(07): 1578-1585 . 本站查看
    47. 倪旭，王宪波. 王宪波教授治疗原发性胆汁性肝硬化的经验. 中西医结合肝病杂志. 2023(07): 652-653+659 .
    48. 王安婧，王亚亚，梁轩，闫雅婕，苏静，李彩东. 基于PPAR治疗胆汁淤积性肝病的机制与药物研究进展. 中国临床药理学与治疗学. 2023(07): 796-808 .
    49. 肖巧，肖华，王容，赵川. 原发性胆汁性胆管炎伴嗜酸性肉芽肿性血管炎一例. 新医学. 2023(08): 601-605 .
    50. 李江硕，尹航，张美娟，侯梦雨，吴竞轩，董瑞华. 基于FARES数据库的奥贝胆酸不良反应真实世界研究. 现代药物与临床. 2023(08): 2061-2066 .
    51. 姚尚娟，李依琳，陈明洁，李强. 自身免疫性肝病重叠综合征的诊断和治疗. 临床肝胆病杂志. 2023(08): 1952-1957 . 本站查看
    52. 苏超，冯月香，郝长河，焦克德. 耳尖放血联合祛湿止痒方治疗黄疸性皮肤瘙痒的临床研究. 中国卫生标准管理. 2023(16): 111-115 .
    53. 王翠，王芬，陈林. 遂宁市中心医院2006～2022年常见非感染性肝病分布特征及变化趋势分析. 现代消化及介入诊疗. 2023(05): 573-577 .
    54. 于盈盈，唐晓颇，吕文良. 原发性胆汁性胆管炎并发骨质疏松研究现状. 中西医结合肝病杂志. 2023(08): 761-765 .
    55. 徐志远，杨永峰. 2012-2021年南京市第二医院肝病住院患者疾病谱及变化趋势分析. 临床肝胆病杂志. 2023(09): 2137-2144 . 本站查看
    56. 吴海梅，赵真真，周永，薛枫，辛永宁，宣世英. 原发性胆汁性胆管炎病人咽漱液中EB病毒分型. 青岛大学学报(医学版). 2023(04): 513-517 .
    57. 周辉，牛斌，宓余强，刘勇钢，李萍. 血清补体C3对原发性胆汁性胆管炎相关肝纤维化分期的诊断价值. 临床肝胆病杂志. 2023(11): 2596-2606 . 本站查看
    58. 王春秋，张晓菲，田诗涵. 青海地区自身免疫性肝病的临床特征分析. 高原医学杂志. 2023(03): 19-24 .
    59. 黄春洋，刘燕敏. 重视不典型自身免疫性肝病患者的早诊早治. 临床肝胆病杂志. 2022(04): 748-753 . 本站查看
    60. 闫惠平，刘燕敏，张海萍. 近二十年我国自身免疫性肝病领域发展历程的回顾与展望. 临床肝胆病杂志. 2022(04): 737-742 . 本站查看
    61. 梁雪莹，丁惠国. 胆源性肝脏疾病消化内镜的诊断与治疗. 中华肝脏病杂志. 2022(07): 690-695 .
    62. 郑鑫淼，苏春芝，马雯，兰慧，万曼曼，张桐，张瑜. 苏春芝主任中医师基于“乙癸同源”论治原发性胆汁性胆管炎. 河北中医药学报. 2022(05): 46-48 .
    63. 林秋香，李圣聪，林爱芳，黄祖雄. 自身免疫抗体谱及抗核抗体核型检测在自身免疫性肝病中的诊断价值. 热带医学杂志. 2022(11): 1507-1510 .
    64. 王石中，苏晓岚，涂雨落，彭憬，孙克伟. 孙克伟教授辨治原发性胆汁性胆管炎经验. 湖南中医药大学学报. 2022(11): 1927-1931 .

    Other cited types(28)

  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 21.7 %FULLTEXT: 21.7 %META: 55.7 %META: 55.7 %PDF: 22.6 %PDF: 22.6 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 4.6 %其他: 4.6 %其他: 1.5 %其他: 1.5 %Baden: 0.0 %Baden: 0.0 %Canada: 0.2 %Canada: 0.2 %Canton: 0.3 %Canton: 0.3 %Central District: 0.1 %Central District: 0.1 %China: 1.2 %China: 1.2 %Ethiopia: 0.1 %Ethiopia: 0.1 %Falls Church: 0.0 %Falls Church: 0.0 %India: 0.1 %India: 0.1 %Indonesia: 0.1 %Indonesia: 0.1 %Malaysia: 0.0 %Malaysia: 0.0 %Malvern: 0.0 %Malvern: 0.0 %Perth Amboy: 0.0 %Perth Amboy: 0.0 %Poland: 0.1 %Poland: 0.1 %Research: 0.1 %Research: 0.1 %Russian Federation: 0.1 %Russian Federation: 0.1 %San Lorenzo: 0.0 %San Lorenzo: 0.0 %Seattle: 0.0 %Seattle: 0.0 %Twinsburg: 0.0 %Twinsburg: 0.0 %United States: 0.1 %United States: 0.1 %Yamanobe: 0.0 %Yamanobe: 0.0 %[]: 0.3 %[]: 0.3 %三明: 0.0 %三明: 0.0 %上海: 8.5 %上海: 8.5 %不列颠哥伦比亚: 0.0 %不列颠哥伦比亚: 0.0 %东京: 0.2 %东京: 0.2 %东京都: 0.1 %东京都: 0.1 %东莞: 0.5 %东莞: 0.5 %中卫: 0.5 %中卫: 0.5 %中山: 0.1 %中山: 0.1 %临汾: 0.1 %临汾: 0.1 %临沂: 0.1 %临沂: 0.1 %临沧: 0.0 %临沧: 0.0 %丽水: 0.1 %丽水: 0.1 %乌鲁木齐: 0.2 %乌鲁木齐: 0.2 %乐山: 0.1 %乐山: 0.1 %九江: 0.1 %九江: 0.1 %仙桃: 0.0 %仙桃: 0.0 %休斯敦: 0.0 %休斯敦: 0.0 %休斯顿: 0.0 %休斯顿: 0.0 %伦敦: 0.0 %伦敦: 0.0 %佛山: 0.2 %佛山: 0.2 %佛罗里达州: 0.0 %佛罗里达州: 0.0 %佳木斯: 0.1 %佳木斯: 0.1 %保定: 0.2 %保定: 0.2 %信阳: 0.0 %信阳: 0.0 %六安: 0.0 %六安: 0.0 %六盘水: 0.0 %六盘水: 0.0 %兰州: 0.5 %兰州: 0.5 %内江: 0.0 %内江: 0.0 %凉山: 0.1 %凉山: 0.1 %包头: 0.1 %包头: 0.1 %北京: 11.1 %北京: 11.1 %匹兹堡: 0.0 %匹兹堡: 0.0 %十堰: 0.1 %十堰: 0.1 %南京: 3.1 %南京: 3.1 %南充: 0.2 %南充: 0.2 %南宁: 0.5 %南宁: 0.5 %南昌: 0.5 %南昌: 0.5 %南通: 0.4 %南通: 0.4 %南阳: 0.1 %南阳: 0.1 %卡纳塔克: 0.0 %卡纳塔克: 0.0 %厦门: 0.4 %厦门: 0.4 %台北: 0.0 %台北: 0.0 %台州: 0.3 %台州: 0.3 %台湾省: 0.0 %台湾省: 0.0 %合肥: 0.4 %合肥: 0.4 %吉列: 0.0 %吉列: 0.0 %吉林: 0.4 %吉林: 0.4 %吉隆坡: 0.0 %吉隆坡: 0.0 %呼伦贝尔: 0.0 %呼伦贝尔: 0.0 %呼和浩特: 0.2 %呼和浩特: 0.2 %咸宁: 0.1 %咸宁: 0.1 %哈尔滨: 0.4 %哈尔滨: 0.4 %哥伦布: 0.0 %哥伦布: 0.0 %唐山: 0.2 %唐山: 0.2 %商丘: 0.0 %商丘: 0.0 %喀什: 0.1 %喀什: 0.1 %嘉兴: 0.1 %嘉兴: 0.1 %嘉峪关: 0.0 %嘉峪关: 0.0 %四平: 0.0 %四平: 0.0 %固原: 0.0 %固原: 0.0 %圣克拉拉: 0.0 %圣克拉拉: 0.0 %墨尔本: 0.0 %墨尔本: 0.0 %大同: 0.0 %大同: 0.0 %大庆: 0.0 %大庆: 0.0 %大连: 0.5 %大连: 0.5 %天津: 1.3 %天津: 1.3 %天门: 0.0 %天门: 0.0 %太原: 0.7 %太原: 0.7 %奥马哈: 0.0 %奥马哈: 0.0 %威海: 0.1 %威海: 0.1 %孝感: 0.0 %孝感: 0.0 %宁波: 0.3 %宁波: 0.3 %安康: 0.3 %安康: 0.3 %安阳: 0.1 %安阳: 0.1 %安顺: 0.1 %安顺: 0.1 %宜宾: 0.0 %宜宾: 0.0 %宜昌: 0.1 %宜昌: 0.1 %宜春: 0.1 %宜春: 0.1 %宝鸡: 0.2 %宝鸡: 0.2 %宣城: 0.1 %宣城: 0.1 %宿迁: 0.1 %宿迁: 0.1 %密蘇里城: 0.1 %密蘇里城: 0.1 %岳阳: 0.1 %岳阳: 0.1 %川崎: 0.0 %川崎: 0.0 %巴中: 0.0 %巴中: 0.0 %巴音郭楞: 0.0 %巴音郭楞: 0.0 %常州: 0.3 %常州: 0.3 %广安: 0.0 %广安: 0.0 %广州: 2.6 %广州: 2.6 %庆阳: 0.0 %庆阳: 0.0 %廊坊: 0.1 %廊坊: 0.1 %张家口: 0.5 %张家口: 0.5 %徐州: 0.3 %徐州: 0.3 %德宏: 0.1 %德宏: 0.1 %德罕: 0.1 %德罕: 0.1 %德阳: 0.0 %德阳: 0.0 %忻州: 0.1 %忻州: 0.1 %怀化: 0.0 %怀化: 0.0 %惠州: 0.2 %惠州: 0.2 %成都: 2.7 %成都: 2.7 %扬州: 0.4 %扬州: 0.4 %抚州: 0.0 %抚州: 0.0 %拉萨: 0.0 %拉萨: 0.0 %攀枝花: 0.0 %攀枝花: 0.0 %文山: 0.0 %文山: 0.0 %文昌: 0.0 %文昌: 0.0 %新乡: 0.2 %新乡: 0.2 %新加坡: 0.2 %新加坡: 0.2 %无锡: 0.4 %无锡: 0.4 %日喀则: 0.0 %日喀则: 0.0 %日照: 0.0 %日照: 0.0 %旭川: 0.1 %旭川: 0.1 %昆明: 1.8 %昆明: 1.8 %昌吉: 0.0 %昌吉: 0.0 %昭通: 0.0 %昭通: 0.0 %晋中: 0.4 %晋中: 0.4 %晋城: 0.0 %晋城: 0.0 %曲靖: 0.0 %曲靖: 0.0 %曼谷: 0.0 %曼谷: 0.0 %朝阳: 0.2 %朝阳: 0.2 %来宾: 0.0 %来宾: 0.0 %杭州: 2.4 %杭州: 2.4 %枣庄: 0.0 %枣庄: 0.0 %查尔斯顿: 0.0 %查尔斯顿: 0.0 %柳州: 0.1 %柳州: 0.1 %株洲: 0.1 %株洲: 0.1 %桂林: 0.1 %桂林: 0.1 %梅州: 0.0 %梅州: 0.0 %梧州: 0.1 %梧州: 0.1 %榆林: 0.1 %榆林: 0.1 %武汉: 1.7 %武汉: 1.7 %毕节: 0.0 %毕节: 0.0 %永州: 0.0 %永州: 0.0 %汉中: 0.1 %汉中: 0.1 %汕头: 0.2 %汕头: 0.2 %江门: 0.2 %江门: 0.2 %沈阳: 0.9 %沈阳: 0.9 %沧州: 0.3 %沧州: 0.3 %河池: 0.0 %河池: 0.0 %泉州: 0.2 %泉州: 0.2 %泰安: 0.1 %泰安: 0.1 %泰州: 0.1 %泰州: 0.1 %泸州: 0.0 %泸州: 0.0 %洛杉矶: 0.1 %洛杉矶: 0.1 %洛阳: 0.1 %洛阳: 0.1 %济南: 1.9 %济南: 1.9 %海东: 0.0 %海东: 0.0 %海东地区: 0.1 %海东地区: 0.1 %海口: 0.1 %海口: 0.1 %海得拉巴: 0.1 %海得拉巴: 0.1 %淄博: 0.2 %淄博: 0.2 %淮北: 0.1 %淮北: 0.1 %淮南: 0.0 %淮南: 0.0 %淮安: 0.1 %淮安: 0.1 %深圳: 1.7 %深圳: 1.7 %清远: 0.1 %清远: 0.1 %温州: 0.1 %温州: 0.1 %渭南: 0.0 %渭南: 0.0 %湘潭: 0.1 %湘潭: 0.1 %湘西: 0.0 %湘西: 0.0 %湛江: 0.2 %湛江: 0.2 %滨州: 0.1 %滨州: 0.1 %漯河: 0.1 %漯河: 0.1 %漳州: 0.1 %漳州: 0.1 %潍坊: 0.4 %潍坊: 0.4 %潜江: 0.0 %潜江: 0.0 %澳门特别行政区: 0.2 %澳门特别行政区: 0.2 %濮阳: 0.0 %濮阳: 0.0 %烟台: 0.1 %烟台: 0.1 %玉溪: 0.1 %玉溪: 0.1 %珠海: 0.1 %珠海: 0.1 %琼海: 0.0 %琼海: 0.0 %白城: 0.0 %白城: 0.0 %百色: 0.1 %百色: 0.1 %盐城: 0.1 %盐城: 0.1 %盘锦: 0.1 %盘锦: 0.1 %眉山: 0.2 %眉山: 0.2 %石家庄: 0.9 %石家庄: 0.9 %福州: 0.8 %福州: 0.8 %秦皇岛: 0.2 %秦皇岛: 0.2 %纽瓦克: 0.0 %纽瓦克: 0.0 %纽约: 0.1 %纽约: 0.1 %纽约州: 0.0 %纽约州: 0.0 %绍兴: 0.1 %绍兴: 0.1 %绥化: 0.0 %绥化: 0.0 %绵阳: 0.1 %绵阳: 0.1 %罗奥尔凯埃: 0.0 %罗奥尔凯埃: 0.0 %聊城: 0.0 %聊城: 0.0 %肇庆: 0.0 %肇庆: 0.0 %舟山: 0.1 %舟山: 0.1 %芒廷维尤: 13.0 %芒廷维尤: 13.0 %芜湖: 0.0 %芜湖: 0.0 %芝加哥: 0.2 %芝加哥: 0.2 %苏州: 0.9 %苏州: 0.9 %荆州: 0.1 %荆州: 0.1 %莆田: 0.1 %莆田: 0.1 %莫斯科: 0.2 %莫斯科: 0.2 %莱芜: 0.1 %莱芜: 0.1 %萍乡: 0.1 %萍乡: 0.1 %萨默维尔: 0.1 %萨默维尔: 0.1 %蚌埠: 0.1 %蚌埠: 0.1 %衡水: 0.1 %衡水: 0.1 %襄阳: 0.1 %襄阳: 0.1 %西双版纳: 0.0 %西双版纳: 0.0 %西孟加拉邦: 0.0 %西孟加拉邦: 0.0 %西宁: 2.5 %西宁: 2.5 %西安: 0.9 %西安: 0.9 %许昌: 0.0 %许昌: 0.0 %贵港: 0.0 %贵港: 0.0 %贵阳: 0.3 %贵阳: 0.3 %费利蒙: 0.1 %费利蒙: 0.1 %资阳: 0.1 %资阳: 0.1 %赣州: 0.1 %赣州: 0.1 %赤峰: 0.1 %赤峰: 0.1 %辽阳: 0.0 %辽阳: 0.0 %达州: 0.1 %达州: 0.1 %运城: 0.3 %运城: 0.3 %连云港: 0.1 %连云港: 0.1 %遂宁: 0.1 %遂宁: 0.1 %遵义: 0.1 %遵义: 0.1 %邢台: 0.0 %邢台: 0.0 %邯郸: 0.3 %邯郸: 0.3 %郑州: 2.0 %郑州: 2.0 %郴州: 0.0 %郴州: 0.0 %都伯林: 0.0 %都伯林: 0.0 %鄂州: 0.1 %鄂州: 0.1 %重庆: 2.4 %重庆: 2.4 %金华: 0.2 %金华: 0.2 %铁岭: 0.1 %铁岭: 0.1 %银川: 0.1 %银川: 0.1 %锡林郭勒盟: 0.1 %锡林郭勒盟: 0.1 %锦州: 0.1 %锦州: 0.1 %镇江: 0.1 %镇江: 0.1 %长春: 2.3 %长春: 2.3 %长春市朝阳区: 0.0 %长春市朝阳区: 0.0 %长沙: 1.4 %长沙: 1.4 %长治: 0.2 %长治: 0.2 %阜阳: 0.1 %阜阳: 0.1 %防城港: 0.1 %防城港: 0.1 %陇南: 0.0 %陇南: 0.0 %随州: 0.0 %随州: 0.0 %雅安: 0.0 %雅安: 0.0 %青岛: 0.8 %青岛: 0.8 %鞍山: 0.1 %鞍山: 0.1 %韶关: 0.0 %韶关: 0.0 %香港特别行政区: 0.0 %香港特别行政区: 0.0 %马尼拉: 0.0 %马尼拉: 0.0 %马鞍山: 0.0 %马鞍山: 0.0 %鸡西: 0.0 %鸡西: 0.0 %黄冈: 0.0 %黄冈: 0.0 %黄山: 0.0 %黄山: 0.0 %黄石: 0.0 %黄石: 0.0 %黔东南: 0.0 %黔东南: 0.0 %黔南: 0.1 %黔南: 0.1 %龙岩: 0.1 %龙岩: 0.1 %其他其他BadenCanadaCantonCentral DistrictChinaEthiopiaFalls ChurchIndiaIndonesiaMalaysiaMalvernPerth AmboyPolandResearchRussian FederationSan LorenzoSeattleTwinsburgUnited StatesYamanobe[]三明上海不列颠哥伦比亚东京东京都东莞中卫中山临汾临沂临沧丽水乌鲁木齐乐山九江仙桃休斯敦休斯顿伦敦佛山佛罗里达州佳木斯保定信阳六安六盘水兰州内江凉山包头北京匹兹堡十堰南京南充南宁南昌南通南阳卡纳塔克厦门台北台州台湾省合肥吉列吉林吉隆坡呼伦贝尔呼和浩特咸宁哈尔滨哥伦布唐山商丘喀什嘉兴嘉峪关四平固原圣克拉拉墨尔本大同大庆大连天津天门太原奥马哈威海孝感宁波安康安阳安顺宜宾宜昌宜春宝鸡宣城宿迁密蘇里城岳阳川崎巴中巴音郭楞常州广安广州庆阳廊坊张家口徐州德宏德罕德阳忻州怀化惠州成都扬州抚州拉萨攀枝花文山文昌新乡新加坡无锡日喀则日照旭川昆明昌吉昭通晋中晋城曲靖曼谷朝阳来宾杭州枣庄查尔斯顿柳州株洲桂林梅州梧州榆林武汉毕节永州汉中汕头江门沈阳沧州河池泉州泰安泰州泸州洛杉矶洛阳济南海东海东地区海口海得拉巴淄博淮北淮南淮安深圳清远温州渭南湘潭湘西湛江滨州漯河漳州潍坊潜江澳门特别行政区濮阳烟台玉溪珠海琼海白城百色盐城盘锦眉山石家庄福州秦皇岛纽瓦克纽约纽约州绍兴绥化绵阳罗奥尔凯埃聊城肇庆舟山芒廷维尤芜湖芝加哥苏州荆州莆田莫斯科莱芜萍乡萨默维尔蚌埠衡水襄阳西双版纳西孟加拉邦西宁西安许昌贵港贵阳费利蒙资阳赣州赤峰辽阳达州运城连云港遂宁遵义邢台邯郸郑州郴州都伯林鄂州重庆金华铁岭银川锡林郭勒盟锦州镇江长春长春市朝阳区长沙长治阜阳防城港陇南随州雅安青岛鞍山韶关香港特别行政区马尼拉马鞍山鸡西黄冈黄山黄石黔东南黔南龙岩1/2

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article has an altmetric score of 7
    Article views (3166) PDF downloads(1274) Cited by(92)
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2941]YesterdayPV[5274]TodayIP[2088]TodayPV[3474]Online[71]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return